The systemic autoinflammatory disorders for dermatologists. Part 2: disease examples.
Amyloidosis
/ etiology
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Biological Products
/ therapeutic use
Colchicine
/ therapeutic use
Cryopyrin-Associated Periodic Syndromes
/ diagnosis
Dermatologists
/ statistics & numerical data
Familial Mediterranean Fever
/ diagnosis
Fever
/ diagnosis
Hereditary Autoinflammatory Diseases
/ diagnosis
Humans
Immune System Diseases
/ complications
Immunity, Innate
/ genetics
Inflammation
/ pathology
Interleukin 1 Receptor Antagonist Protein
/ adverse effects
Interleukin-1
/ immunology
Mevalonate Kinase Deficiency
/ diagnosis
Receptors, Interleukin-1
/ deficiency
Receptors, Interleukin-6
/ antagonists & inhibitors
Schnitzler Syndrome
/ diagnosis
Skin Diseases, Genetic
/ diagnosis
Steroids
/ therapeutic use
Tubulin Modulators
/ therapeutic use
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
09
03
2020
accepted:
11
03
2020
pubmed:
4
9
2020
medline:
29
7
2021
entrez:
4
9
2020
Statut:
ppublish
Résumé
The systemic autoinflammatory disorders (SAIDS) or periodic fever syndromes are disorders of innate immunity, which can be inherited or acquired. They are almost all very rare and easily overlooked; typically, patients will have seen multiple specialities prior to diagnosis, so a high level of clinical suspicion is key. It is important to note that these are 'high-value' diagnoses as the majority of these syndromes can be very effectively controlled, dramatically improving quality of life and providing protection against the development of irreversible complications such as AA amyloidosis. In Part 1 of this review, we took an overview of SAIDS and described the common features; in this article, we take a more in-depth look at the better recognized or more dermatologically relevant conditions.
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Biological Products
0
IL1RL2 protein, human
0
Interleukin 1 Receptor Antagonist Protein
0
Interleukin-1
0
Receptors, Interleukin-1
0
Receptors, Interleukin-6
0
Steroids
0
Tubulin Modulators
0
Colchicine
SML2Y3J35T
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
967-973Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
Lachmann HJ, Lowe P, Felix SD et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 11: 1029-36.
Rowczenio DM, Melo Gomes S, Aróstegui JI et al. Late-onset cryopyrin-associated periodic syndromes caused by somatic NLRP3 mosaicism-UK single center experience. Front Immunol 2017; 8: 1410.
Levy R, Gérard L, Kuemmerle-Deschner J et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis 2015; 74: 2043-9.
Kieffer C, Cribier B, Lipsker D. Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 2009; 88: 23-31.
Hawkins PN, Lachmann HJ, Aganna E et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50: 607-12.
Kullenberg T, Löfqvist M, Leinonen M et al. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxford) 2016; 55: 1499-506.
Hoffman HM, Throne ML, Amar NJ et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58: 2443-52.
Lachmann HJK-PI, Kuemmerle-Deschner JB, Leslie KS et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17: 25-31.
Stoffels M, Szperl A, Simon A et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Ann Rheum Dis 2014; 73: 455-61.
Park YH, Wood G, Kastner DL et al. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 2016; 17: 914-21.
Lachmann HJ, Sengul B, Yavuzsen TU et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006; 45: 746-50.
Tunca M, Akar S, Onen F et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine 2005; 84: 1-11.
Twig G, Livneh A, Vivante A et al. Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann Rheum Dis 2014; 73: 704-9.
Ozen S, Demirkaya E, Erer B et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 2016; 75: 644-51.
Ben-Zvi I, Kukuy O, Giat E et al. Anakinra for colchicine-resistant familial mediterranean fever: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2017; 69: 854-62.
Bachetti T, Ceccherini I. Tumor necrosis factor receptor-associated periodic syndrome as a model linking autophagy and inflammation in protein aggregation diseases. J Mol Med (Berl) 2014; 92: 583-94.
Lachmann HJ, Papa R, Gerhold K et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 2014; 71: 2035-43.
Lane T, Loeffler JM, Rowczenio DM et al. AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 2013; 65: 1116-21.
Ter Haar N, Lachmann H, Özen S et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72: 678-85.
De Benedetti F, Gattorno M, Anton J et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 2018; 378: 1908-19.
Munoz MA, Jurczyluk J, Mehr S et al. Defective protein prenylation is a diagnostic biomarker of mevalonate kinase deficiency. J Allergy Clin Immunol 2017; 140: 873-5.
van der Burgh R, Pervolaraki K, Turkenburg M et al. Unprenylated RhoA contributes to IL-1β hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity. J Biol Chem 2014; 289: 27757-65.
Ter Haar NM, Jeyaratnam J, Lachmann HJ et al. The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the Eurofever registry. Arthritis Rheum 2016; 68: 821-30.
Lane T, Gillmore JD, Wechalekar AD et al. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. Clin Exp Rheum 2015; 33(Suppl): S46-53.
Simon A, Asli B, Braun-Falco M et al. Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy 2013; 68: 562-8.
Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis 2010; 5: 38.
de Koning HD, Bodar EJ, van der Meer JW et al. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007; 37: 137-48.
Krause K, Weller K, Stefaniak R et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 2012; 67: 943-50.
de Koning HD, Schalkwijk J, van der Meer JW et al. Successful canakinumab treatment identifies IL-1beta as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol 2011; 128: 1352-4.
de Koning HD, Bodar EJ, Simon A et al. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis 2006; 65: 542-4.
Aksentijevich I, Masters SL, Ferguson PJ et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426-37.
Reddy S, Jia S, Geoffrey R et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009; 360: 2438-44.
Farooq M, Nakai H, Fujimoto A et al. Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. Hum Mutat 2013; 34: 176-83.
Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-8.
Onoufriadis A, Simpson MA, Pink AE et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011; 89: 432-7.
Rossi-Semerano L, Piram M, Chiaverini C et al. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics 2013; 132: e1043-7.